Roche Holding Ltd. company operates two segments, pharmaceuticals and diagnostics, and sells its products in more than 150 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Herceptin, anemia treatment NeoRecormon/Epogin, hepatitis drug Pegasys, transplant drug CellCept, obesity treatment Xenical, and Tamiflu, which is used to prevent and treat influenza, including avian strains. The company markets many of its bestsellers through subsidiary Genentech and affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers advanced DNA tests, diabetes monitoring supplies, and point-of-care diagnostics used in a variety of health care settings.

American Oriental Bioengineering, Inc. (AOB) is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. The Company’s business comprises prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA). The Company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and cities in China. During the year ended December 31, 2008, AOB marketed over 60 pharmaceutical products in China. On October 18, 2008, the Company acquired Nuo Hua Investment Company Limited. On October 20, 2008, the Company acquired GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd.

Since its founding in 2004, Anthera Pharmaceuticals' operations have consisted primarily of research and development activities. A biopharmaceutical company, Anthera Pharmaceuticals develops drug treatments for respiratory, cardiovascular, and immunological diseases. Its current candidates, which are in various phases of clinical development, include therapies for acute coronary syndrome (inflammation of heart muscle), lupus, and sickle cell disease. The company also has treatments for asthma and dermatitis in earlier stages of development. The company filed an initial public offering (IPO) in mid-2009.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Light Sciences Oncology, Inc. company is in the business of developing its proprietary Light Infusion Therapy (Litx). Litx is a novel treatment for solid tumors, in which a flexible light-emitting diode (LED) is inserted into a tumor, followed by an injection of Aptocine (talaporfin sodium), a light-activated drug. Once the LED activates Aptocine, molecular oxygen is converted into singlet oxygen, killing tissue within the LED's scope and shutting down the blood supply to the area. The treatment is designed for use on cancers including liver and prostate cancers and glioma (brain tumors).

GeneFluidics, Inc. develops electrochemical sensor platform for molecular analysis. Its solutions perform bioassays with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays. The company’s products include sensor chip arrays; Proteus, a modular robotic system; and Asklepios, the multi-channel microfluidics cartidge system. Its products are used for human diagnostics, animal health, environmental monitoring, and blood banking applications. The company was incorporated in 2000 and is headquartered in Monterey Park, California.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Diosynth Biotechnology is all about the cGMP and protein. The company is a leading provider of cGMP (Current Good Manufacturing Practices) production for recombinant therapeutic proteins and peptides. Diosynth's line of proteins include monoclonal antibodies, cancer vaccines, fusion proteins, hormones, cancer vaccines, and anti-coagulants. The company also offers contract manufacturing, process development, and validation services. Diosynth has manufacturing facilities in the US, serving a wide range of customers. The company (which originally began operating in 1923) was a subsidiary of Akzo Nobel until Schering-Plough bought that company's pharmaceutical operations in 2007.

Isagenix International company develops and manufactures a range of health and wellness products from nutritional and dietary supplements to skin care products and systems. Isagenix's line of "Nutritional Cleansing" products help improve health by accelerating the removal of impurities from the body and by replacing the impurities with nutrients to revive health. The company also offers dietary supplements to help customers lose weight and increase energy. A network marketing enterprise, Isagenix provides the products and sales support services to its international network of associates, relying on its associates to sell the products and recruit new associates.

NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.